Novo Nordisk must face US shareholder suit over CagriSema trial
A US court let investor claims proceed over the company's disclosures surrounding the cagrilintide-semaglutide obesity program.
DO
By Daniel Okafor · Regulatory Correspondent
Jul 28 03:00 ETSource: Yahoo Finance
The wire
- 01A US judge ruled Novo Nordisk must defend a shareholder lawsuit tied to its CagriSema clinical trial disclosures.
- 02Litigation over how obesity trial expectations were communicated adds legal risk to the most-watched incretin combination program in the pipeline.
- 03Surviving a motion to dismiss is not a finding of liability; the case still has to be litigated and Novo has not conceded the claims.
From the source
Read at finance.yahoo.comNovo Nordisk must face US shareholder lawsuit over CagriSema clinical trial
